Phenylpropenamide_NP Derivatives_NP AT-61_NP and_CC AT-130_NP Inhibit_NP Replication_NP of_IN Wild-Type_NP and_CC Lamivudine-Resistant_NP Strains_NP of_IN Hepatitis_NP B_NP Virus_NP In_IN Vitro_NP The_DT phenylpropenamide_NN derivatives_NNS AT-61_NP and_CC AT-130_NP are_VBP nonnucleoside_JJ analogue_NN inhibitors_NNS of_IN hepatitis_NP B_NP virus_NN (_( HBV_NP )_) replication_NN ._SENT They_PP inhibited_VBD the_DT replication_NN of_IN wild-type_NP HBV_NP with_IN 50_CD %_NN inhibitory_JJ concentrations_NNS of_IN 21.2_CD +-_NN 9.5_CD and_CC 2.40_CD +-_NN 0.92_CD muM_NN ,_, respectively_RB ,_, compared_VBN to_TO 0.064_CD +-_NN 0.020_CD muM_NN lamivudine_NP ._SENT There_EX were_VBD no_DT significant_JJ differences_NNS in_IN sensitivity_NN between_IN wild-type_NN and_CC nucleoside_NN analogue-resistant_NN (_( rtL180M_NP ,_, rtM204I_NP ,_, and_CC rtL180M_NNS +_SYM rtM204V_NP )_) HBV_NP ._SENT Chronic_JJ hepatitis_NP B_NP virus_NN (_( HBV_NP )_) infection_NN ,_, a_DT major_JJ cause_NN of_IN hepatocellular_JJ carcinoma_NN and_CC liver_NN cirrhosis_NN ,_, affects_VBZ about_RB 5_CD %_NN of_IN the_DT world_NN 's_POS human_JJ population_NN ._SENT Chronic_JJ HBV_NP infection_NN is_VBZ unresponsive_JJ to_TO currently_RB available_JJ vaccines_NNS and_CC can_MD only_RB be_VB controlled_VBN by_IN chemotherapy_NN ._SENT In_IN most_JJS countries_NNS ,_, only_RB two_CD drugs_NNS ,_, alpha_NN interferon_NN (_( IFN-alpha_NP )_) ,_, and_CC lamivudine_NP (_( LMV_NP )_) [_SYM (-)-beta-L-2'-3'-dideoxy-3'-thiacytidine_NN ]_SYM ,_, are_VBP approved_VBN for_IN treatment_NN of_IN chronic_JJ HBV_NP ,_, but_CC additional_JJ drugs_NNS are_VBP being_VBG developed_VBN ._SENT IFN_NP treatment_NN results_NNS in_IN a_DT sustained_JJ response_NN in_IN only_RB a_DT minority_NN of_IN cases_NNS and_CC may_MD be_VB associated_VBN with_IN dose-limiting_VBG side_NN effects_NNS ._SENT LMV_NP ,_, a_DT deoxycytidine_NN analog_NN ,_, is_VBZ a_DT safer_JJR and_CC more_JJR effective_JJ inhibitor_NN of_IN HBV_NP replication_NN ,_, but_CC its_PP$ effects_NNS are_VBP rarely_RB sustained_VBN after_IN short-term_JJ treatment_NN ,_, and_CC its_PP$ long-term_JJ use_NN frequently_RB results_VBZ in_IN the_DT emergence_NN of_IN drug-resistant_JJ HBV_NP strains_NNS ._SENT Specific_JJ mutations_NNS associated_VBN with_IN resistance_NN to_TO LMV_NP have_VBP been_VBN identified_VBN by_IN sequence_NN analysis_NN and_CC shown_VBN to_TO affect_VB the_DT catalytic_JJ YMDD_NN (_( tyrosine-methionine-aspartate-aspartate_NN )_) motif_NN of_IN the_DT viral_JJ polymerase_NN ._SENT Because_IN they_PP are_VBP genotype_NN dependent_JJ ,_, the_DT numbering_VBG systems_NNS used_VBN to_TO identify_VB these_DT mutations_NNS are_VBP confusing_JJ ;_: as_IN a_DT result_NN ,_, the_DT adoption_NN of_IN a_DT standardized_JJ genotype-independent_NN nomenclature_NN has_VBZ recently_RB been_VBN proposed_VBN and_CC is_VBZ used_VBN here_RB ._SENT The_DT LMV_NP resistance_NN mutations_NNS that_WDT have_VBP been_VBN observed_VBN most_RBS frequently_RB in_IN clinical_JJ isolates_NNS cause_VBP the_DT methionine_NN at_IN amino_NN acid_NN residue_NN 204_CD in_IN the_DT reverse_JJ transcriptase_NN coding_VBG region_NN of_IN the_DT polymerase_NN protein_NN (_( formerly_RB amino_NN acid_NN 539_CD ,_, 549_CD ,_, 550_CD ,_, or_CC 552_CD ,_, depending_VBG on_IN the_DT genotype_NN )_) to_TO be_VB replaced_VBN with_IN either_DT isoleucine_NN or_CC valine_NN ._SENT These_DT changes_NNS are_VBP identified_VBN as_IN rtM204I_NP and_CC rtM204V_NP ,_, respectively_RB ,_, by_IN the_DT new_JJ nomenclature_NN ._SENT While_IN the_DT rtM204I_NN substitution_NN alone_RB appears_VBZ to_TO be_VB sufficient_JJ to_TO confer_VB resistance_NN to_TO LMV_NP ,_, rtM204V_NP is_VBZ rarely_RB observed_VBN in_IN the_DT absence_NN of_IN a_DT second_JJ mutation_NN that_WDT causes_VBZ an_DT upstream_JJ substitution_NN of_IN methionine_NN for_IN leucine_NN at_IN reverse_JJ transcriptase_NN residue_NN 180_CD (_( rtL108M_NN ;_: formerly_RB identified_VBN as_IN polymerase_NN residue_NN 515_CD ,_, 525_CD ,_, 526_CD ,_, or_CC 528_CD )_) ._SENT Interestingly_RB ,_, the_DT rtL180M_NN change_NN ,_, by_IN itself_PP ,_, has_VBZ been_VBN associated_VBN with_IN resistance_NN to_TO famciclovir_NN ,_, another_DT nucleoside_NN analogue_NN that_WDT has_VBZ undergone_VBN clinical_JJ trials_NNS against_IN chronic_JJ HBV_NP infection_NN ._SENT Several_JJ independent_JJ studies_NNS have_VBP provided_VBN evidence_NN that_IN mutations_NNS that_WDT confer_VBP resistance_NN to_TO LMV_NP and/or_CC famciclovir_NP also_RB confer_VBP resistance_NN to_TO other_JJ nucleoside_NN analogs_NNS (_( ,_, ,_, ,_, ,_, ,_, ;_: reviewed_VBN in_IN reference_NN )_) ._SENT Cross-resistance_NP may_MD therefore_RB limit_VB the_DT clinical_JJ potential_NN of_IN some_DT nucleoside_NN analogs_NNS that_WDT are_VBP being_VBG developed_VBN as_IN potential_JJ anti-HBV_NP agents_NNS ._SENT The_DT identification_NN of_IN safe_JJ and_CC efficacious_JJ nonnucleoside_JJ inhibitors_NNS of_IN HBV_NP replication_NN would_MD greatly_RB improve_VB prospects_NNS for_IN overcoming_VBG the_DT problems_NNS associated_VBN with_IN nucleoside_NN analog_NN cross-resistance_NN ._SENT Although_IN several_JJ low-molecular-weight_NN nonnucleoside_JJ anti-HBV_NP compounds_NNS have_VBP been_VBN identified_VBN (_( reviewed_VBN in_IN reference_NN )_) ,_, very_RB few_JJ have_VBP been_VBN tested_VBN in_IN controlled_VBN clinical_JJ trials_NNS ._SENT The_DT phenylpropenamide_NN derivative_JJ AT-61_NP was_VBD recently_RB shown_VBN to_TO be_VB a_DT potent_JJ inhibitor_NN of_IN in_IN vitro_NP HBV_NP replication_NN in_IN stably_RB or_CC transiently_RB transfected_JJ HepG2_NP cells_NNS ._SENT AT-61_NP specifically_RB inhibited_VBD the_DT in_IN vitro_NN replication_NN of_IN HBV_NP but_CC had_VBD no_DT effect_NN on_IN the_DT in_IN vitro_NN replication_NN of_IN a_DT variety_NN of_IN other_JJ viruses_NNS ,_, including_VBG duck_NN HBV_NP ,_, woodchuck_NN HBV_NP ,_, or_CC human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NP )_) ._SENT Moreover_RB ,_, AT-61_NP was_VBD found_VBN to_TO be_VB equally_RB active_JJ as_IN an_DT inhibitor_NN of_IN HBV_NP replication_NN in_IN the_DT HepG2-derived_NP HepAD38_NP and_CC HepAD79_NP cell_NN lines_NNS ._SENT In_IN these_DT cell_NN lines_NNS ,_, the_DT expression_NN of_IN stably_RB transfected_JJ HBV_NP genomes_NNS (_( wild_JJ type_NN [_SYM wt_NN ]_SYM in_IN HepAD38_NP and_CC rtM204V_NP in_IN HepAD79_NP ,_, respectively_RB )_) is_VBZ controlled_VBN by_IN a_DT tetracycline-sensitive_JJ promoter_NN ._SENT It_PP was_VBD also_RB reported_VBN that_IN combinations_NNS of_IN AT-61_NP and_CC LMV_NP produced_VBD synergistic_JJ antiviral_JJ effects_NNS against_IN HBV_NP replication_NN in_IN AD38_NP cells_NNS ._SENT These_DT data_NNS suggest_VBP that_IN the_DT specific_JJ anti-HBV_NP activity_NN of_IN AT-61_NP is_VBZ due_JJ to_TO a_DT mechanism(s)_NN that_WDT differs_VBZ from_IN that_DT of_IN LMV_NP ._SENT Furthermore_RB ,_, they_PP imply_VBP that_IN mutations_NNS that_WDT confer_VBP resistance_NN to_TO LMV_NP and_CC other_JJ nucleoside_NN analogs_NNS may_MD not_RB confer_VB cross-resistance_NN to_TO AT-61_JJ or_CC other_JJ phenylpropenamide_NN derivatives_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM Structures_NP of_IN AT-61_NP (_( a_DT )_) and_CC AT-130_NP (_( b_LS )_) ._SENT Structures_NNS of_IN AT-61_NP (_( a_DT )_) and_CC AT-130_NP (_( b_LS )_) ._SENT Mol_NP Wt_NP ._SENT ,_, molecular_JJ weight_NN ._SENT AT-130_NP ,_, a_DT congener_NN of_IN AT-61_NP ,_, differs_VBZ from_IN AT-61_NP in_IN that_WDT rings_NNS A_NP and_CC B_NP contain_VBP ortho-methoxy_NN and_CC para-nitroso_NN substituents_NNS ,_, respectively_RB ;_: in_IN addition_NN ,_, a_DT bromine_NN atom_NN replaces_VBZ the_DT chlorine_NN present_NN in_IN AT-61_NP ._SENT AT-130_NP has_VBZ also_RB been_VBN shown_VBN to_TO have_VB anti-HBV_NP activity_NN in_IN HepAD38_NP cells_NNS in_IN vitro_NN ._SENT The_DT present_JJ study_NN sought_VBD to_TO determine_VB the_DT relative_NN in_IN vitro_NN potencies_NNS of_IN AT-61_NP and_CC AT-130_NP as_IN inhibitors_NNS of_IN wt_NN and_CC nucleoside_NN analog-resistant_JJ HBV_NP replication_NN by_IN using_VBG a_DT recently_RB described_VBN model_NN that_WDT employs_VBZ recombinant_JJ baculoviruses_NNS to_TO efficiently_RB transduce_VB HepG2_JJ cells_NNS with_IN replication-competent_JJ HBV_NP genomes_NNS ._SENT Recombinant_JJ baculoviruses_NNS that_WDT encode_VBP either_DT 1.28-times_NP genome_NN length_NN wt_NP HBV_NP (_( genotype_NN A_NP ,_, subtype_NN adw2_NN )_) or_CC one_CD of_IN three_CD drug-resistant_JJ mutants_NNS were_VBD constructed_VBN and_CC propagated_VBN as_IN described_VBN previously_RB ._SENT The_DT three_CD drug-resistant_JJ viruses_NNS harbored_VBD point_NN mutations_NNS that_WDT coded_VBD for_IN rtL180M_NN ,_, rtM204I_NP ,_, or_CC rtL180M_NNS +_SYM rtM204V_JJ substitutions_NNS in_IN the_DT HBV_NP polymerase_NN sequence_NN ,_, respectively_RB ._SENT AT-61_NP and_CC AT-130_NP were_VBD synthesized_VBN as_IN described_VBN previously_RB ,_, and_CC stock_NN solutions_NNS of_IN each_DT drug_NN were_VBD freshly_RB prepared_VBN in_IN dimethyl_NN sulfoxide_NN ._SENT The_DT final_JJ concentration_NN of_IN dimethyl_NN sulfoxide_NN in_IN the_DT cell_NN culture_NN media_NNS was_VBD always_RB <1%_(vol/vol), rtL180M_NN >_SYM rtL180M_NN +_SYM rtM204V_NP >_SYM rtM204I_NN ,_, assuming_VBG that_IN the_DT transduction_NN efficiencies_NNS were_VBD equal_JJ and_CC that_IN the_DT polymerase_NN changes_NNS did_VBD not_RB differentially_RB affect_VB virus_NN secretion_NN ._SENT The_DT autoradiographs_NNS shown_VBN were_VBD exposed_VBN for_IN different_JJ times_NNS so_RB that_IN the_DT image_NN densities_NNS in_IN the_DT control_NN lanes_NNS are_VBP approximately_RB equal_JJ ._SENT Panels_NNS C_NP and_CC D_NP show_VBP a_DT graphical_JJ analysis_NN of_IN data_NNS derived_VBN from_IN panels_NNS A_NP and_CC B_NP ,_, respectively_RB ._SENT Symbols_NNS :_: *_SYM ,_, wt_NN ;_: ,_, rtM204I_NN ;_: ,_, rtL180M_NN ;_: ,_, rtL180M_NN +_SYM rtM204V_NP ._SENT Preliminary_JJ experiments_NNS confirmed_VBD that_DT treatment_NN with_IN either_DT AT-61_NP or_CC AT-130_NP caused_VBD dose-dependent_JJ inhibition_NN of_IN wt_NP HBV_NP replication_NN in_IN HepG2_JJ cells_NNS and_CC that_IN neither_DT compound_NN was_VBD measurably_RB toxic_JJ to_TO either_DT HepG2_NP or_CC Huh-7_JJ cells_NNS at_IN concentrations_NNS of_IN up_IN to_TO 250_CD muM_NN ,_, the_DT highest_JJS concentration_NN tested_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT Results_NNS from_IN the_DT recombinant_JJ baculovirus_NN assay_NN system_NN produced_VBD estimated_JJ IC50s_NNS of_IN 0.064_CD +-_NN 0.020_CD ,_, 21.2_CD +-_NN 9.5_CD ,_, and_CC 2.4_CD +-_NN 0.92_CD muM_NN (_( mean_VB +-_JJ standard_JJ deviation_NN of_IN triplicate_JJ assays_NNS against_IN wt_NP HBV_NP )_) for_IN LMV_NP ,_, AT-61_NP ,_, and_CC AT-130_NP ,_, respectively_RB ._SENT These_DT IC50s_NNS are_VBP consistent_JJ with_IN the_DT potency_NN ranking_NN reported_VBD earlier_RBR but_CC are_VBP greater_JJR than_IN those_DT reported_VBN previously_RB ,_, i.e._FW ,_, 0.6_CD to_TO 5.7_CD muM_NN for_IN AT-61_NP ,_, depending_VBG on_IN the_DT cell_NN line_NN used_VBN for_IN the_DT assay_NN ,_, and_CC 0.13_CD muM_NN for_IN AT-130_NP ._SENT Subsequent_JJ experiments_NNS compared_VBN the_DT activities_NNS of_IN AT-61_NP and_CC AT-130_NP as_IN inhibitors_NNS of_IN both_DT wt_NN and_CC mutant_JJ HBVs_NP ._SENT The_DT results_NNS ,_, which_WDT are_VBP summarized_VBN in_IN Table_NP ,_, indicate_VBP that_IN the_DT calculated_JJ IC50s_NN and_CC resistance_NN factors_NNS for_IN wt_NN and_CC mutant_JJ HBVs_NNS were_VBD not_RB significantly_RB different_JJ following_NN either_CC AT-61_NP or_CC AT-130_NP treatment_NN ._SENT They_PP also_RB confirmed_VBD that_IN ,_, on_IN a_DT molar_JJ basis_NN ,_, AT-130_NP was_VBD more_RBR effective_JJ as_IN an_DT inhibitor_NN of_IN in_IN vitro_NP HBV_NP DNA_NP replication_NN than_IN was_VBD AT-61_JJ ._SENT Calculated_JJ IC50s_NP and_CC IC90s_NP were_VBD in_IN the_DT ranges_NNS of_IN 19_CD to_TO 27_CD and_CC 63_CD to_TO 97_CD muM_NN ,_, respectively_RB ,_, for_IN AT-61_NP ._SENT The_DT corresponding_JJ ranges_NNS for_IN AT-130_NP were_VBD 1.3_CD to_TO 5.1_CD and_CC 11_CD to_TO 36_CD muM_NN ._SENT To_TO confirm_VB that_IN the_DT phenylpropenamide_NN derivatives_NNS were_VBD active_JJ against_IN LMV-resistant_NP HBV_NP mutants_NNS and_CC to_TO confirm_VB that_IN these_DT mutants_NNS showed_VBD a_DT drug_NN resistance_NN phenotype_NN in_IN vitro_NN ,_, replicate_JJ assays_NNS were_VBD carried_VBN out_RP in_IN parallel_NN with_IN LMV_NP as_IN an_DT internal_JJ control_NN ._SENT The_DT results_NNS presented_VBN in_IN Table_NP confirm_VBP that_IN mutations_NNS that_WDT confer_VBP LMV_NP resistance_NN do_VBP not_RB confer_VB cross-resistance_NN to_TO the_DT phenylpropenamide_NN derivatives_NNS ._SENT TABLE_NN 1_CD |_SYM Sensitivity_NN of_IN wt_NN and_CC drug-resistant_JJ HBV_NP to_TO phenylpropenamide_NN derivatives_NNS AT-61_NP and_CC AT-130_NP TABLE_NP 2_CD |_SYM Relative_JJ sensitivities_NNS of_IN wt_NN and_CC drug-resistant_JJ HBV_NP Results_NNS presented_VBD here_RB confirm_VB and_CC extend_VB previously_RB reported_VBN observations_NNS regarding_VBG the_DT anti-HBV_NP activities_NNS of_IN AT-61_JJ and_CC related_JJ phenylpropenamide_NN derivatives_NNS ._SENT Although_IN the_DT mechanism_NN of_IN action_NN of_IN this_DT group_NN of_IN compounds_NNS is_VBZ unknown_JJ ,_, it_PP appears_VBZ to_TO be_VB independent_JJ of_IN interference_NN with_IN the_DT RNA-_NP or_CC DNA-dependent_NP activities_NNS of_IN the_DT HBV_NP polymerase_NN ._SENT Observing_VBG that_DT exposure_NN to_TO AT-61_NP decreased_VBD the_DT amount_NN of_IN RNA-containing_NP cytoplasmic_JJ HBV_NP core_NN particles_NNS ,_, King_NP and_CC colleagues_NNS postulated_VBD that_IN AT-61_NP inhibits_VBZ the_DT packaging_NN of_IN pregenomic_JJ viral_JJ RNA_NP ,_, a_DT prerequisite_NN for_IN genome_NN replication_NN ._SENT Our_PP$ observation_NN that_IN the_DT HBV_NP mutants_NNS most_RBS commonly_RB associated_VBN with_IN LMV_NP and/or_CC famciclovir_NN resistance_NN remain_VBP sensitive_JJ to_TO both_DT AT-61_NP and_CC AT-130_NP justifies_VBZ the_DT further_JJR development_NN of_IN these_DT compounds_NNS or_CC their_PP$ derivatives_NNS for_IN eventual_JJ clinical_JJ use_NN ._SENT These_DT compounds_NNS appear_VBP to_TO have_VB the_DT potential_NN to_TO arrest_VB the_DT replication_NN of_IN known_VBN drug-resistant_JJ HBV_NP strains_NNS and_CC thus_RB ,_, in_IN combination_NN with_IN nucleoside/nucleotide_NN analogs_NNS and/or_CC other_JJ drugs_NNS ,_, may_MD help_VB reduce_VB ,_, or_CC perhaps_RB even_RB prevent_VB ,_, the_DT development_NN of_IN drug_NN resistance_NN ._SENT 